U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis (CF). The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help develop the therapy.
Developed by Gilead Sciences, Inc., Cayston offers a much-needed antibiotic alternative for CF patients who battle recurrent lung infections and develop resistance to existing antibiotics.
And I CAN'T WAIT to use it!!!!! My docs @ Hopkins told me last month that'd I'd be taking this as soon as it became available. I hear it's done a lot of positive things for those who were in the studies. I love hearing positive breakthroughs like this. Woo Hoo!!! Let's keep em' coming :)
Cabbage and Bacon with Buttery Noodles
3 days ago
